This study evaluates a new contrast agent called HarMono-T used during ultrasound examinations of the kidney. The contrast agent contains perflutren, which helps create better images during kidney imaging procedures. The purpose is to test how safe this contrast agent is and how well it works in creating clear images of the kidneys.
During the study, healthy individuals will receive a single dose of HarMono-T through an intravenous injection. Four different dose levels will be tested. The contrast agent consists of tiny bubbles that improve the visibility of kidney structures during ultrasound imaging. After receiving the injection, participants will undergo kidney ultrasound examinations to assess how well the contrast agent works.
The study will monitor participants’ health through various medical checks, including blood tests and heart monitoring. A final ultrasound examination will be performed 30 minutes after receiving the contrast agent to confirm that it has completely cleared from the body. Participants will be followed for approximately one week after receiving the injection to check for any potential side effects.



Germany